Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Commentary|Videos|February 19, 2026
Patient Selection Considerations for the Bionic Breast Project
Author(s)Stacy Tessler Lindau, MD, MA
Fact checked by: Kyle Doherty
Stacy Tessler Lindau, MD, MA, discusses which patients would be strong fits for the Bionic Breast project.
Advertisement
Stacy Tessler Lindau, MD, MA, discusses which patients should consider enrolling in the Bionic Breast project. She notes that the project is currently focusing on patients who are willing to connect with study investigators twice weekly for several weeks to do electrical testing of the neuroprosthetic implant. Patients will also participate in phone interviews and keep a journal documenting their experience with the procedure.
Advertisement
Related to this article
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
The FDA has granted priority review to a supplemental application for talazoparib plus enzalutamide in HRR-altered mCSPC.
Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
Johannes Schetelig, MD, MSc, discusses phase 3 data for post-transplant cyclophosphamide vs ATLG as GVHD prophylaxis in hematologic malignancies.
Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
3
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
4
European Commission Approves Camizestrant Plus CDK4/6 Inhibition for Emergent ESR1-Mutated Advanced Breast Cancer
5